Trials / Not Yet Recruiting
Not Yet RecruitingNCT06746545
A Prospective, Open-label, Single-arm Phase II Clinical Study of Fruquintinib Combined With S-1 for the Treatment of Metastatic Colorectal Cancer.
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Fujian Cancer Hospital · Other Government
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Exploring the efficacy and safety of fruquintinib combined with S-1 for second-line and beyond treatment in patients with advanced colorectal cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fruquintinib+S-1 | Fruquintinib: 5 mg, oral, once daily，2w/1w；Q3W S-1：40-60 mg (dosed according to body surface area), oral，2w/1w；Q3W |
Timeline
- Start date
- 2025-02-01
- Primary completion
- 2026-08-01
- Completion
- 2027-02-01
- First posted
- 2024-12-24
- Last updated
- 2024-12-24
Source: ClinicalTrials.gov record NCT06746545. Inclusion in this directory is not an endorsement.